Skip to content

US · CORT · MEDICAL - PHARMACEUTICALS

Corcept Therapeutics Incorporated (CORT) intrinsic value and stock valuation

$63.62as of 2026-11-21 · Mkt cap 11.97B

Data updated · price as of 2026-11-21

UndervaluedIC value is 20–50% above the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Corcept Therapeutics Incorporated DCF and intrinsic value

InvestorsCraft values CORT with the Chepakovich two-stage DCF model — currently rated undervalued. How the model works · Run your own DCF prefilled from CORT’s statements →

Corcept Therapeutics Incorporated Graham Number

Graham Number: $11.60d — the price is above the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Medical - Pharmaceuticals Redwood City, CA 94065 corcept.com

How the business is doing

Fiscal 2011–2025, USD

Revenue
$761.4M+16.6% 5y CAGRd
20112025
Net income
$99.7M-1.2% 5y CAGRd
20112025
Free cash flow
$141.8M-1.2% 5y CAGRd
20112025
Total equity
$647.8M+4.4% 5y CAGRd
20112025

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2011–2025, USD
20252024202320222021
Revenue$761.4M$675M$482.4M$401.9M$366M
Operating income$44.8M$137M$107.3M$112.6M$124.5M
Net income$99.7M$139.7M$106.1M$101.4M$112.5M
EPSd$830.5K$1.23M$949.9K$874.5K$893.2K
Operating cash flow$142M$198.1M$127M$120.3M$167.9M
Capital expenditure-$-210K-$-2.17M-$-140K-$-410K-$-470K
Free cash flow$141.8M$195.9M$126.9M$119.9M$167.4M
Total assets$836.7M$840.6M$621.5M$583.4M$423.8M
Total debt$6.11M$6.94M$150K$1.14M$530K
Net debt-$-114.39M-$-120.73M-$-135.4M-$-65.19M-$-77.09M
Total equity$647.8M$679.6M$506.7M$501.8M$375.8M
Cash and short-term investments$372.2M$383.3M$368.2M$431.7M$223.5M
Income statement
20252024202320222021
Revenue$761.4M$675M$482.4M$401.9M$366M
Cost of revenue$13M$10.9M$6.48M$5.38M$5.28M
Gross profit$748.4M$664.2M$475.9M$396.5M$360.7M
Research and development expenses$254.9M$246.9M$184.4M$131M$113.9M
Selling, general and administrative expenses$448.7M$280.3M$184.3M$152.9M$122.4M
Other expenses$0.00$0.00$0.00$0.00$0.00
Operating expenses$703.6M$527.2M$368.6M$283.8M$236.2M
Cost and expenses$716.6M$538.1M$375.1M$289.2M$241.5M
Interest income$21.7M$24.5M$17.3M$3.56M$530K
Interest expense$0.00$0.00$0.00$0.00$0.00
Depreciation and amortization$1.89M$1.34M$1.04M$1.26M$3.07M
Ebitda$68.4M$162.8M$125.6M$117.5M$128M
Operating income$44.8M$137M$107.3M$112.6M$124.5M
Total other income/expenses, net$21.7M$24.5M$17.3M$3.56M$530K
Income before tax$66.5M$161.5M$124.6M$116.2M$125M
Income tax expense-$-33.19M$20.3M$18.4M$14.8M$12.5M
Net income$99.7M$139.7M$106.1M$101.4M$112.5M
Weighted average shares outstanding$103.9M$103.2M$103.6M$106.8M$115.7M
Weighted average diluted shares outstanding$120M$113.5M$111.7M$116M$126M
Balance sheet
20252024202320222021
Cash and short-term investments$372.2M$383.3M$368.2M$431.7M$223.5M
Net receivables$59.8M$58.1M$56.8M$46.9M$29M
Inventory$12.9M$12.4M$7.73M$6.1M$4.99M
Total current assets$485.5M$471.6M$458.6M$499.3M$266.5M
Property, plant and equipment, net$6.47M$8.01M$320K$1.78M$1.52M
Goodwill and intangible assets$0.00$0.00$0.00$0.00$0.00
Long-term investments$160.3M$219.8M$57.2M$4.95M$112.3M
Total non-current assets$351.2M$369M$162.9M$84.2M$157.3M
Total assets$836.7M$840.6M$621.5M$583.4M$423.8M
Accounts payable$40.4M$15.4M$17.4M$12M$6.91M
Short-term debt$1.08M$830K$150K$1.14M$530K
Deferred revenue$35.7M$0.00$0.00$0.00$0.00
Total current liabilities$166.1M$140.8M$104.5M$72.5M$47.5M
Long-term debt$5.02M$6.11M$0.00$0.00$0.00
Deferred revenue, non-current$0.00$0.00$0.00$0.00$0.00
Total non-current liabilities$22.8M$20.2M$10.3M$9.1M$410K
Capital lease obligations$1.08M$6.11M$0.00$0.00$0.00
Total liabilities$188.9M$161M$114.8M$81.6M$48M
Common stock$140K$140K$130K$130K$130K
Retained earnings$643.4M$543.7M$402.5M$296.4M$195M
Accumulated other comprehensive income (loss)$2.26M-$-220K$610K-$-870K-$-230K
Total equity$647.8M$679.6M$506.7M$501.8M$375.8M
Total investments$411.9M$475.5M$289.9M$370.3M$258.2M
Total debt$6.11M$6.94M$150K$1.14M$530K
Net debt-$-114.39M-$-120.73M-$-135.4M-$-65.19M-$-77.09M
Cash flow statement
20252024202320222021
Net income$98.2M$141.2M$106.1M$101.4M$112.5M
Depreciation and amortization$1.89M$1.34M$2.36M$3.45M$3.07M
Stock-based compensation$84.5M$61.4M$48.9M$42.4M$42.9M
Change in working capital-$-27.57M$45.3M$8.22M$5.54M-$-60K
Accounts receivable-$-5.81M$1.15M-$-10.07M-$-17.43M-$-1.43M
Inventory-$-7.48M$300K$1.26M$1.2M$3.44M
Accounts payable$25.1M-$-2.25M$5.78M$4.76M-$-3.6M
Net cash provided by operating activities$142M$198.1M$127M$120.3M$167.9M
Investments in property, plant and equipment-$-210K-$-2.17M-$-140K-$-410K-$-470K
Acquisitions, net$0.00$0.00$0.00$0.00-$-136.59M
Net cash used for investing activities$69.8M-$-177.6M$90.9M-$-114.33M$136.1M
Common stock issued$0.00$9.62M$0.00$0.00$0.00
Common stock repurchased-$-245.86M-$-15.66M-$-145.43M$0.00-$-295.99M
Dividends paid$0.00$0.00$0.00$0.00$0.00
Net cash used for financing activities-$-220.37M-$-28.35M-$-148.72M-$-17.28M-$-302.59M
Net change in cash-$-7.17M-$-7.89M$69.2M-$-11.29M$1.43M
Cash at end of period$120.5M$127.7M$135.6M$66.3M$77.6M
Operating cash flow$142M$198.1M$127M$120.3M$167.9M
Capital expenditure-$-210K-$-2.17M-$-140K-$-410K-$-470K
Free cash flow$141.8M$195.9M$126.9M$119.9M$167.4M
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Corcept Therapeutics Incorporated

        Corcept Therapeutics Incorporated, founded in 1998 and headquartered in Menlo Park, California, is a pharmaceutical firm dedicated to the discovery, development, and commercialization of treatments for serious metabolic, oncological, and neuropsychiatric disorders across the United States. Its primary commercial offering is Korlym (mifepristone) tablets, an oral medication taken once daily. Korlym is prescribed for adult patients diagnosed with endogenous Cushing's syndrome who suffer from hyperglycemia due to hypercortisolism, particularly those with type 2 diabetes or glucose intolerance, and for whom surgical options have either failed or are not viable. The company's development pipeline is robust, featuring relacorilant, which is being advanced for Cushing's syndrome. It is also investigating a combination of relacorilant with nab-paclitaxel; this pairing has concluded Phase II clinical trials for advanced ovarian tumors and is additionally being studied for conditions involving cortisol excess. Furthermore, Corcept is developing distinct selective cortisol modulators for specific indications such as metastatic castration-resistant prostate cancer and antipsychotic-induced weight gain, alongside research into FKBP5 gene expression assays.

        CEO
        Joseph K. Belanoff
        Employees
        730
        Beta
        0.46

        Included in

        Explore

        Frequently asked questions

        What is the intrinsic value of Corcept Therapeutics Incorporated (CORT)?

        Corcept Therapeutics Incorporated (CORT) is currently undervalued based on the InvestorsCraft IC model — IC value is 20–50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is CORT undervalued?

        CORT trades at a price of $63.62 (Nov 21, 2026): undervalued — IC value is 20–50% above the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.